Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

Phase 2
4(57.1%)
N/A
2(28.6%)
Phase 4
1(14.3%)
7Total
Phase 2(4)
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT07565623Not ApplicableNot Yet Recruiting

Prevention of AIDS With Opportunistic Infection Paradoxical IRIS

Role: collaborator

NCT07538882Recruiting

AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma

Role: collaborator

NCT07526363Not Yet Recruiting

Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections

Role: collaborator

NCT07179653Phase 2Active Not Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

Role: collaborator

NCT07170345Recruiting

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Role: collaborator

NCT04669496Phase 2Active Not Recruiting

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Role: collaborator

NCT05979935Active Not Recruiting

A Digital Tongue Diagnosis Model for High- and Low-risk Esophagogastroduodenal Varices in Cirrhosis

Role: collaborator

NCT06280105Phase 2Recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Role: lead

NCT05409482Recruiting

A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

Role: lead

NCT05129904Unknown

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

Role: collaborator

NCT05986383Unknown

Multi-center Clinical Study on the Decision Tree of Precision Hepatectomy in China Precision Hepatectomy Decision Tree

Role: collaborator

NCT04962958Phase 2Unknown

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Role: collaborator

NCT05140837Unknown

Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)

Role: collaborator

NCT05739110Completed

HCC Staging Modified by Tumor Micronecrosis

Role: collaborator

NCT05433935Recruiting

Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

Role: collaborator

NCT03884673Recruiting

Dolutegravir Plus Lamivudine Simplified Therapy

Role: collaborator

NCT04125654Not ApplicableUnknown

Metagenomic Next-Generation Sequencing for Diagnosis of Ascites Infection in End-stage Liver Diseases

Role: collaborator

NCT04119973Completed

A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China

Role: collaborator

NCT03515369Phase 4Unknown

Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma

Role: collaborator

All 19 trials loaded